We are discovering gene therapies for the treatment of rare monogenic kidney diseases
Our mission is to cure genetic kidney diseases by discovering, developing and commercializing novel medicines.
Ninevah Therapeutics (NTX) lead discovery program is an AAV-based approach for podocyte-associated genetic disorders (NTX014). Our goal is to translate NTX014 from discovery to a first-in-human trial (FIH).
NTX is building a 2nd discovery program on a gene editing approach for non-AAV targetable larger genes.
Ninevah Therapeutics was founded in Barcelona Q2-2019.